Visualization of Protein-Drug Interactions for the Analysis of Drug Resistance in Lung Cancer

Area of Science:

• Oncology
• Molecular Biology
• Computational Chemistry

Background:

• Non-small cell lung cancer (NSCLC) driven by epidermal growth factor receptor (EGFR) mutations is a leading cause of cancer death.
• Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective initially but often fail due to acquired resistance mutations.
• Understanding the atomic-level mechanisms of EGFR-TKI resistance is crucial for developing more effective therapies.

Purpose of the Study:

• To investigate the molecular mechanisms underlying drug resistance in EGFR-mutated NSCLC.
• To analyze EGFR-drug interactions and identify key residues involved in resistance.
• To establish a systematic method for visualizing protein-drug interactions for resistance analysis.

Main Methods:

• Molecular dynamics (MD) simulations were employed to model EGFR-drug interactions.
• Analysis included calculating Euclidean distance and binding free energy to assess drug resistance.
• Principal component analysis (PCA) was used to identify critical protein residues involved in drug interactions.

Main Results:

• MD simulations provided insights into the dynamics of EGFR-drug interactions.
• Binding free energy and distance metrics correlated with observed drug resistance.
• PCA successfully identified normal, rigid, flexible, and critical residues influencing drug binding.

Conclusions:

• A systematic framework for analyzing drug resistance in NSCLC at the atomic level has been established.
• The proposed method effectively visualizes protein-drug interactions, aiding in understanding resistance mechanisms.
• This approach can inform the design of next-generation EGFR-TKIs to overcome drug resistance.